3 active not recruiting, 2 terminated, 1 completed. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Terminated 2, Completed 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow utomilumab: new trials by email Literature Review of utomilumab trials Research Report on utomilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide - COL6A3 Positive, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 5 | 2018-09-04 | 2024-11-07 |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Vinorelbine, Trastuzumab, Avelumab - Breast Cancer | Phase 2 | Active not recruiting | Adrienne G. Waks | 100 | 2018-06-21 | 2026-07-20 |
| Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Utomilumab, ISA101b - Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2018-04-04 | 2022-12-16 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Avelumab, Utomilumab, PF-04518600 - Advanced Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 409 | 2015-11-09 | 2024-07-30 |
Breast Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Neoplasm Metastasis (1) · Oropharyngeal Neoplasms (1) · Ovarian Neoplasms (1) · Papillomavirus Infections (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
M.D. Anderson Cancer Center (3) · Adrienne G. Waks (1) · Laura Huppert, MD, BA (1) · Pfizer (1)
United States (6) · Australia (1) · Canada (1) · France (1) · Japan (1) · Poland (1) · Taiwan (1) · United Kingdom (1)
Adrienne Waks, MD, PhD (1) · Amir A Jazaeri (1) · Aung Naing (1) · Bonnie S. Glisson, BS,MD (1) · Laura Huppert, MD (1)
2015 (1)